Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,571.20 +0.73%
EUR-USD 1.2570 0.1157%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 90.86 +0.22%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: NASDAQ GS
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Generic Drugs

Impax Laboratories Inc

Add to Portfolio

IPXL:US

21.2300 USD 0.0300 0.14%

As of 20:10:00 ET on 05/25/2012.

Snapshot for Impax Laboratories Inc (IPXL)

Open: 21.2300 Day's Range: 21.1300 - 21.3500 Volume: 193,446 Bid: 21.2000
Previous Close: 21.2000 52wk Range: 14.4600 - 27.2600 1-Yr Rtn: -21.89% Ask: 21.2300

Stock Chart for IPXL

No chart data available.
  • IPXL:US 21.2300
  • 1D
  • 1M
  • 1Y
21.2000
Interactive IPXL Chart

Previous Close

Key Statistics for IPXL

Current P/E Ratio (ttm) 15.3841
Estimated P/E (12/2012) 11.6970
Earnings Per Share (USD) (ttm) 1.3800
Est. EPS (USD) (12/2012) 1.8150
Est. PEG Ratio 0.4974
Market Cap (M USD) 1,422.58
Shares Outstanding (M) 67.01
Enterprise Value (M USD) (ttm) 1,079.36
Enterprise Value/EBITDA (ttm) 8.77
Price/Book (mrq) 2.2714
Price/Sale (ttm) 2.5725
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 08/02/2012
More IPXL Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for IPXL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)
More IPXL Income Statement Data
  • Total Assets
  • Total Liabilities (M/USD)
  • Debt to Assets (%)
More IPXL Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/USD)
More IPXL Cash Flow Data

Company Profile & Key Executives for IPXL

Impax Laboratories, Inc. develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The Company specializes in the development of niche and controlled release generics, as well as the development of branded products.

Robert L BurrChairmanLarry HsuPresident/CEO
Carole S Ben-MaimonPres:Global PharmaceuticalsMichael J NestorPres:Impax Pharmaceuticals
More Company Profile & Key Executives for IPXL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements